

Statewide Cancer Strategy Kick-Off May 11, 2018

Statewide Cancer Strategy Taking Aim at Cancer in Louisiana: Cancer in Louisiana Landscape Analysis and Collaboration Opportunity

May 11, 2018




Louisiana cancer incidence and mortality rates exceed U.S. rates by 7% and 13% respectively, with a handful of cancers causing a disproportionate share of the suffering.

Average Annual # Deaths & Mortality per 100,000 (Age-Adjusted)							
	Louisiana (2	U.S. (2011-2015) ²					
Cancer Type	Average Annual # Deaths	Mortality Rate	Mortality Rate				
Lung	2,701	53.6	43.4				
Breast (female)	651	23.7	20.9				
Prostate	412	21.6	19.5				
Colorectal	874	17.5	14.5				
Pancreas	653	13.1	10.9				
All Cancer	9,362	187.8	163.5				



By reducing Louisiana's cancer mortality rates to the national average, <u>1,500 fewer Louisianans would die each year from cancer.</u>

Persistent and large racial disparities exist among the five most common cancers.



Sources: Louisiana Tumor Registry

manatt

The concentration of cancer care delivery and payment signal that by working together, we can make significant in-roads in reducing the devastating impact of cancer in Louisiana.

Eight health systems provide +80% of inpatient cancer care

Baton Rouge General Franciscan Missionaries of Our Lady Health System HCA Lafayette General Health LCMC Ochsner St. Tammany Willis Knighton Health Ten payers cover vast majority of cancer patients

Aetna AmeriGroup Blue Cross Blue Shield Cigna Humana Louisiana Healthcare Connections Medicaid (Fee for Service) Medicare (Fee for service) Peoples United




Objective	To improve cancer outcomes in Louisiana by expanding resident access to cancer prevention, screening and standard of care treatment	
Guiding Principles	 Fact-based & transparent dialogue Broad-based decision-making Coordination & alignment 	
Initial Interventions	 Colorectal cancer screening Breast cancer treatment 	



Colorectal Cancer Screening Louisiana's Current State & Proposed Intervention

A CRC intervention focused on improved access to screening can reverse state trends of high mortality and high treatment cost due to late stage diagnoses.



Colorectal Cancer Screening


Proposed Intervention Highlights

- Mobile medical clinics
- Navigator program
- Screening and treatment guidelines
- Incentives for providers and patients
- Public education and outreach
- Screening rate targets

Note: Respondents fifty years of age and older who have not had a blood stool test within the past two years Source: Louisiana Comprehensive Cancer Control Plan 2017-2021.

manatt

Existing outliers in breast cancer treatment and costs in Louisiana may be reduced via an intervention focused on improving outcomes and reducing treatment variation.




Cancer Treatment: Outlier Episodes

Proposed Intervention Highlights

- Community standard of care
- Provider & payer engagement in guideline development

- Community-based clinical trial
- Care bundles & incentives
- Process & outcome measures



manatt

Proposed Roadmap

The committees will launch initial interventions in the first year, refine/enhance approaches in the second, and demonstrate value and results to support longer term planning in the third.

	Year 0	Year 1	Year 2	Year 3
Executive Committee	 Define operating model Constitute committees and charters Identify and retain Director Define initial targets & set annual goals 	Select year two interventionsFundraising	Select year three interventionsFundraising	 Direct development of next three-year strategic plan Select new fundraising target
Clinical Committee	Assess and define initial priorities including target conditions and associated interventions	 Define and implement guidelines and interventions Define and implement program elements Recruit sites/physician champions as needed 	 Refine interventions and guidelines Recommend year 2+ priority areas and interventions 	 Contribute to evaluation of clinical intervention impact Recommend guidelines and interventions to support strategy
Policy Committee	Conduct economic impact analysisAssess cost of care variation	 Convene stakeholders to define and prioritize intervention recommendations Define short-term policy and programmatic changes that are needed to promote better access, reduced cost, and higher quality 	Implement short-term policy and programmatic changes	Contribute to evaluation of impact of short-term policy and programmatic changes
Data & Reporting Committee	 Assess mortality rate and incidence Identify variation in care, treatment patterns, cost and utilization outliers Define service provision Define disparity parameters 	 Assess variations, high cost clinical areas Define measures (clinical, financial, access, experience) Establish baseline measure and reporting Begin any new data collection for baseline 	 Continue to refine registry, claims, and other data collection elements Measure & publish results (i.e. baseline Y1 outcomes) 	Lead evaluation of interventions and generate reports
Staff	Director recruited and on-boarded	 Facilitate committees, selection and implementation of interventions Facilitate fundraising 	 Facilitate committees, selection and implementation of interventions Facilitate fundraising 	 Facilitate committees, development of three-year strategic plan Facilitate fundraising

ELIMINATING COLORECTAL CANCER DISPARITIES IN LOUISIANA: A PUBLIC HEALTH CONUNDRUM

Charles R. Rogers, PhD, MPH, MS, CHES[®] Assistant Professor

Dept. of Family Medicine & Community Health

University of Minnesota Medical School



Louisiana Statewide Cancer Strategy Kickoff

Division of Administration Claiborne Building Baton Rouge, LA Friday, May 11, 2018



UNIVERSITY OF MINNESOTA







THE PROBLEM

Colorectal Cancer (CRC)

- 2nd leading cancer <u>killer</u> among African Americans (and Cajuns)
 - 3rd leading cause of <u>death</u>

• Compared to Whites, African Americans (AAs) have:


- Poorer survival once diagnosed
- Lower 5-year relative survival
- Compared to White men, AA men (AAM) live sicker & die younger
 - 27% † CRC incidence
 - <u>52%</u> † CRC mortality





THE PROBLEM


OTA



THE PROBLEM

Louisiana has the 4th highest CRC mortality rate in the U.S.!

- High mortality is partially driven by LA's CRC incidence rate, which is the <u>third</u> <u>highest</u> in the country
- The high incidence rate is related to Lynch syndrome amongst the Cajun population, who have a CRC incidence rate that is 23% higher than the average U.S. population
- Lower than average screening rates also contribute to higher mortality; 1/3 of Louisianans over the age of 50 have never had an endoscopy



ERSITY OF MINNESOTA




CRC is preventable & curable, yet disparities exist

BIG or small we want to see them all GET A COLONOSCOPY

Screening: <u>effective</u> test to detect precancerous polyps so they can be removed before turning into cancer.



Low CRC screening rates result in <u>more late stage diagnoses, higher mortality, & higher cost.</u>




- Louisiana Tumor Registry, Louisiana Cancer Prevention & Control Program;
- Louisiana Comprehensive Cancer Control Plan 2017-2021,
- 2004-2010, American Cancer Society: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosisstaging/survival-rates.html
- Medicare spending, in: Styperek, A.; Kimball, A.B. Malignant Melanoma: The Implications of Cost for Stakeholder Innovation. Am. J. Pharm. Benef. 2012, 4, 66–76.



JNIVERSITY OF MINNESOTA









DR. ROGERS' PAST RESEARCH

"A Progress Report of African American Men's Intentions to Screen for CRC in Minnesota"



Purpose: Test a conceptual model of factors influencing intentions to screen for CRC among African American men (ages 18-65) in Minnesota employing on-line survey research methods.

<u>Central hypothesis</u>: [1] male role norms (masculinity) indirectly influence these men's intentions to screen via perceived barriers; [2] these men **lack** the appropriate knowledge and espouse **negative** attitudes toward CRC screening.




Rogers, Goodson, Dietz, & Okuyemi (2016)



Items included in 6 Prize Drawings Apple AppleTV1080P Amazon Kindle FireHD 51" Plasma HDTV Beats by Dre Google Solo HD Headphones Nexus 7 Tablet Apple iPad Mini Supported by: Masonic Cancer Center Program in Health **Disparities Research** UNIVERSITY OF MINNESOTA www.healthdisparities.umn.edu Medical School minnesota cancer alliance **Q** Health Connections working together to eliminate the burden of cancer A division of Southside Community Health Services, Inc. GASTROENTEROLOGY, P.A. Premier Gastroenterology Care For more information/questions, contact the Primary Investigator, Dr. Charles R. Rogers, at: crrogers@umn.edu or 612-626-3894





- Of 286 study participants, 223 (78%) indicated they planned to obtain CRC screening in the future.
- Age (β = 1.507, χ 2 = 28.119, p < 0.0001) was significantly (& positively) associated with CRC screening intention when demographic variables alone are considered.
- Age (β = 1.861, χ2 = 25.696, p < 0.0001) & perceived subjective norms (β = 1.269, χ2 = 23.124, p < 0.0001) were significant predictors of CRC screening intent.
- Alike, Age (β = 1.916, χ2 = 21.732, p < 0.0001) & perceived barriers (negatively) (β = -0.853, χ2 = 8.404, p = 0.0037).
 University of Minnesota

Rogers, Goodson, Dietz, & Okuyemi (2016)

SHIFTING POLITICAL PARADIGMS IN LOUISIANA



"Minnesota should lower the recommended CRC screening age for African Americans"

- The fact that CRC treatment costs are rising at a *higher* rate than the average *increase* in health costs is unacceptable since costs associated with this preventable disease are *cheaper* if caught earlier (Fight Colorectal Cancer, 2012).
 - Nationally, patients diagnosed with CRC in early stages have the *lowest* treatment costs (\$27,551)
 - Followed by patients with distant stage (\$29,933), &
 - Patients with advanced CRC having the *highest* cost (\$30,748) (Luao et al., 2009).

Colon Cancer: the disease no one has to die from.

-Rogers, C.R. (January, 2015)



Prince's home state: the land of 10,000 disparities.

-Rogers, C.R. (July, 2016)



Opportunities for CRC Screening Intervention Success

CRC screening initiatives across the country have been shown to reduce incidence & mortality, and may be feasible to implement at a statewide level in Louisiana.

Delaware Cancer Consortium (DCC): statewide CRC screening program •<u>Who?</u>

- With state legislature \$\$\$, DE Govenor Minner developed the program in 2003
- DE law tasked DCC with coordinating cancer prevention & control activities
- DCC members included: reps from the DE House of Representatives & State Senate, the Governor's Office, the Sec. of the Department of Health & Social Services, & cancer center physicians

•<u>How?</u>

- Insurance coverage for screening
- Use of nurse navigators to conduct screening outreach & recruitment
- Treatment for those with a CRC diagnosis

Successful?

- 41% CRC mortality rate decrease in AAs (compared to 13% decrease in Whites)
- 34% CRC incidence rate decrease in AAs (compared to 26% decrease in Whites)
- While the DCC screening costs approximately \$1 million annually, the program saved <u>\$8.5 million annually</u> from reduced CRC incidence & earlier stage diagnoses.
- From 2003-2011, the program provided <u>5,000+</u> CRC screenings.
 - "The results we achieved in DE can be replicated across the country..." -Congressman John Carney



Opportunities for CRC Screening Intervention Success

- Kentucky CRC Program (2001) focuses on increasing CRC screening. The program resulted in 24% reduction in CRC incidence & 30% reduction in CRC mortality (2002-2012).
- New Hampshire CRC Screening Program offered <u>patient navigation services</u> for CRC screening. The program resulted in 96% of navigated patients received CRC screening, compared to 69% of non-navigated patients.
- South Carolina CRC Prevention Network provided open access colonoscopy to uninsured residents of SC through <u>statewide partnerships and patient navigation</u>: improved screening, drastically reduced no-show rates, & resulted in ~90% good to excellent bowel preparation.
- HealthPartners (MN health care provider & health insurance company) launched <u>Fecal</u> <u>Immunochemical Test (FIT) kit</u>-focused pilot projects to improve screening rates. With FIT instructions & follow-up call reminders (both in 7 different languages), their disparity gap was narrowed by 11% for patients of color aged 50-75 not current with CRC screening (2009-2017)



ACKNOWLEDGMENTS

- Participants who made these studies possible
- Community Partners
- Co-Authors, Research Teams
- Funders
- Louisiana Department of Health
- Carrie Vogelsang, MPH







crrogers@umn.edu @crrogersPhD





GASTROENTEROLOGY, P.A. Premier Gastroenterology Care





NIVERSITY OF MINNESOTA




A Statewide Quality Improvement Collaborative: Michigan Oncology Quality Consortium (MOQC)


May 11, 2018 Louisiana Cancer Strategy Kick Off Event

Douglas W. Blayney, MD Stanford Cancer Institute Clinical Excellence Research Center, Stanford

Quality

- Outcome
- Process
- Structure
- Because testing the effect of an intervention on survival takes years...
- Focus on processes
 - Develop evidence-based guidelines
 - Measure adherence to guidelines
 - Targeted interventions to improve adherence





Quality Oncology Practice Initiative (QOPI°)

- Outpatient practice-based voluntary program
- Foster a culture of self-examination and improvement in
- Facilitate performance improvement
- Measures oncology care processes
- Measures are

 Evidence-based
 Guideline-based
 Consensus-based


 Continually reviewed and thereence to processes of processes of care








Growth





From 2006 to 2010, 308 unique practice groups with approximately 2,100 physicians participated in at least one of the 10 possible rounds of data collection.

JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Measuring the Improving Quality of Outpatient Care in Medical Oncology Practices in the United States

Published Ahead of Print on March 11, 2013 as 10,1200/JCO.2012.43,3300


The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.43.3300

Michael O. Neuss, Jennifer L. Malin, Stephanie Chan, Pamela J. Kadlubek, John L. Adams, Joseph O. Jacobson, Douglas W. Blayney, and Joseph V. Simone

ASCO's QOPI Program shows most practices have maxed out on treatment process measures

QOPI Process Improvement Large Academic Medical Center





Blayney, et al, JCO 27:3802, 2009



Home

Links

About Us

Resources

Publications

Particinant Locations

MICHIGAN ONCOLOGY QUALITY C

HOME ABOUT US RESOURCES PARTICIPANT LOCATIONS PUBLICATION



Friday June 24th 11:30- 4 pm

Biannual Conference Update

Location: The Henry in Dearborn Keynote Speaker: J. Cameron Muir, MD FAAHPM, Past Preside Academy of Hospice & Palliative Medicine Target Audience: Physicians, Nurses, and Managers


MOOC HOME

MOOC Participant Locations



Physician groups: •


- Develop consensus guidelines
- Review data
- Develop interventions
- **Coordinating Center** •
 - Coordinate meetings
 - Support interventions
 - Hold confidential data and data use agreements
 - Chart abstraction
- ASCO
 - QOPI is a member benefit
 - Practice-level reports
- Payers
 - Provide support
 - Claims data



Performance Of Medical Practice Groups In The Michigan Oncology Quality Consortium (MOCQ) On Process Measures For Pain Management For New Patients, Fall 2010

Blayney, et al. Health Affairs 2012 Apr;31(4):729.

HealthAffairs




improved over time

Performance Of Medical Practice Groups In The Michigan Oncology Quality Consortium (MOCQ) On Process Measures, Spring 2009–Spring 2011

Blayney, et al. Health Affairs 2012 Apr;31(4):729.


QI Activity #1: KRAS Results





MI vs. National QOPI Scores: KRAS testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy (Higher Score- Better)

QI Activity #2: Pain Management Results (Summer 2010-Fall 2011)





Critical Success Factors

- <u>Guidelines</u>
 - Evidenced based
 - Local modifications
 - No payer input
- <u>Coordinating center</u>
 - Build consensus
 - Committee of local experts
 - Neutral, unbiased third party
 - Confidential data
 - Move slowly (no initial "naming and shaming")
- Payer and Business Community
 - Commitment to right care, right patient, right time

Challenges and Barriers

- Overcoming provider reluctance
- Data abstraction
- Data use agreements (!start early!)
- IT support
- No claims data from payers
- Implementation science (?what's that?)

COMMUNITY CANCER CARE IN WASHINGTON STATE Quality and Cost Report 2018

VERSION 1 | MAY 1, 2018


FRED HUTCH

HICOR

HUTCHINSON INSTITUTE FOR CANCER OUTCOMES RESEARCH

1B: RECOMMENDED TREATMENT FOR BREAST CANCER

Figure 1B.4: Recommended treatment for breast cancer



Summary Quality Score Range: -6.4% to 1.8%

Cost Range: \$63,132 to \$88,942

Quality

- Outcome
- Process

• Structure

- Because testing the effect of an intervention on survival takes years...
- Focus on processes
 - Develop evidence-based guidelines
 - Measure adherence to guidelines
 - Targeted interventions to improve adherence



Health

unvival

Downloaded from content.healthaffairs.org by Health Affairs on June 14, 2014 by guest




INTERVIEW

A Founder of Quality Assessment Encounters A Troubled System Firsthand

Shortly before his death, Avedis Donabedian talked with Fitzhugh Mullan about health care and the management of his own cancer care.

by Fitzhugh Mullan



Toxicity management Indirect costs (lost work, travel, etc)

